This page contains a Flash digital edition of a book.
Surgery and Interventional Radiology Collaborate on Combination Therapy in Hepatocellular Carcinoma hepatocellular carcinoma, Hepatology, 2002;35:1164–71.


35. Bruix J, Sherman M, Llovet JM, et al., Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, 2001;35:421–30.


36. Marelli L, Stigliano R, Triantos C, et al., Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies, Cardiovasc Intervent Radiol, 2007;30:6–25.


37. Coldwell DM, Stokes KR, Yakes WF, Embolotherapy: agents, clinical applications, and techniques, Radiographics, 1994;14:623–43.


38. Rand T, Loewe C, Schoder M, et al., Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate, Cardiovasc Intervent Radiol, 2005;28:313–8.


39. Gerunda GE, Neri D, Merenda R, et al., Role of transarterial chemoembolization before liver resection for hepatocarcinoma, Liver Transpl, 2000;6:619–26.


40. Hanjan T, De Sanctis J, Hepatic arterial interventions, In: Ray CE, Hichks ME, Patel NH (eds), SIR Syllabus: Interventions in Oncology, Fairfax, VA: Society of Interventional Radiology, 2003;103–18.


41. Lewis AL, Gonzalez MV, Lloyd AW, et al., DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization, J Vasc Interv Radiol, 2006;17:335–42.


42. Lammer J, Malagari K, Vogl T, et al., Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Intervent Radiol, 2010;33:41–52.


43. Carr BI, Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients, Liver Transpl, 2004;10:S107–10.


44. Kooby DA, Egnatashvili V, Srinivasan S, et al., Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma, J Vasc Interv Radiol, 2010;21:224–30.


45. Salem R, Lewandowski RJ, Mulcahy MF, et al., Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 2010;138:52–64.


46. Salem R, Lewandowski RJ, Kulik L, et al., Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology,


2011;140(2):497–507.e2.


47. Kulik LM, Atassi B, van Holsbeeck L, et al., Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation, J Surg Oncol, 2006;94:572–86.


48. Lewandowski RJ, Kulik LM, Riaz A, et al., A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization, Am J Transplant, 2009;9:1920–8.


49. Ogihara M, Wong LL, Machi J, Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes, HPB (Oxford), 2005;7:214–21.


50. Rossi S, Garbagnati F, Lencioni R, et al., Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply, Radiology, 2000;217:119–26.


51. Livraghi T, Meloni F, Di Stasi M, et al., Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?, Hepatology, 2008;47:82–9.


52. Lencioni RA, Allgaier HP, Cioni D, et al., Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio- frequency thermal ablation versus percutaneous ethanol injection, Radiology, 2003;228:235–40.


53. Lin SM, Lin CJ, Lin CC, et al., Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm, Gastroenterology, 2004;127:1714–23.


54. Shiina S, Teratani T, Obi S, et al., A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma, Gastroenterology, 2005;129:122–30.


55. Iwatsuki S, Starzl TE, Sheahan DG, et al., Hepatic resection versus transplantation for hepatocellular carcinoma, Ann Surg, 1991;214:221–8.


56. Pichlmayr R, Weimann A, Oldhafer KJ, et al., Appraisal of transplantation for malignant tumours of the liver with special reference to early stage hepatocellular carcinoma, Eur J Surg Oncol, 1998;24:60–7.


57. Imamura H, Matsuyama Y, Tanaka E, et al., Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy, J Hepatol, 2003;38:200–7.


58. Poon RT, Fan ST, Ng IO, et al., Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma, Cancer, 2000;89:500–7. 59. Patt CH, Thuluvath PJ, Role of liver transplantation in the


management of hepatocellular carcinoma, J Vasc Interv Radiol, 2002;13:S205–10.


60. Mazzaferro V, Regalia E, Doci R, et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 1996;334:693–9.


61. Ismail T, Angrisani L, Gunson BK, et al., Primary hepatic malignancy: the role of liver transplantation, Br J Surg, 1990;77:983–7.


62. Pichlmayr R, Weimann A, Steinhoff G, et al., Liver transplantation for hepatocellular carcinoma: clinical results and future aspects, Cancer Chemother Pharmacol, 1992;31(Suppl.):S157–61.


63. Selby R, Kadry Z, Carr B, et al., Liver transplantation for hepatocellular carcinoma, World J Surg, 1995;19:53–8.


64. Lau WY, Primary liver tumors, Semin Surg Oncol, 2000;19:135–44. 65. Bismuth H, Morino M, Sherlock D, et al., Primary treatment of hepatocellular carcinoma by arterial chemoembolization, Am J Surg, 1992;163:387–94.


66. Penn I, Hepatic transplantation for primary and metastatic cancers of the liver, Surgery, 1991;110:726–34.


67. Klintmalm G, Discussion on: Hepatic transplantation for primary and metastatic cancers of the liver, Surgery, 1991;110:734–5.


68. Busuttil RW, Discussion on: Hepatic resection versus transplantation for hepatocellular carcinoma, Ann Surg, 1991;214:228–9.


69. Goldstein DA, Oda Y, Kurokawa K, et al., Blood levels of 25-hydroxyvitamin D in nephrotic syndrome. Studies in 26 patients, Ann Intern Med, 1977;87:664–7.


70. Beavers KL, Sandler RS, Shrestha R, Donor morbidity associated with right lobectomy for living donor liver transplantation to adult recipients: a systematic review, Liver Transpl, 2002;8:110–7.


71. Pascher A, Sauer IM, Walter M, et al., Donor evaluation, donor risks, donor outcome, and donor quality of life in adult-to-adult living donor liver transplantation, Liver Transpl, 2002;8:829–37.


72. Kim-Schluger L, Florman SS, Schiano T, et al., Quality of life after lobectomy for adult liver transplantation, Transplantation, 2002;73:1593–7.


73. Sarasin FP, Majno PE, Llovet JM, et al., Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective, Hepatology, 2001;33:1073–9.


74. Bolondi L, Piscaglia F, Camaggi V, et al., Review article: liver transplantation for HCC. Treatment options on the waiting list, Aliment Pharmacol Ther, 2003;17(Suppl. 2):145–50.


US GASTROENTEROLOGY & HEPATOLOGY REVIEW


49


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76